Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 167-179 , April 2009

Therapeutic management of adrenal insufficiency

References 

  1. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361:1881–1893
  2. Lovas K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison's disease. Clinical Endocrinology. 2002;56:581–588
  3. Hahner S, Loeffler M, Fassnacht M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. The Journal of Clinical Endocrinology and Metabolism. 2007;92:3912–3922
  4. Thomsen AF, Kvist TK, Andersen PK, et al. The risk of affective disorders in patients with adrenocortical insufficiency. Psychoneuroendocrinology. 2006;31:614–622
  5. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, et al. Premature mortality in patients with Addison's disease: a population-based study. The Journal of Clinical Endocrinology and Metabolism. 2006;91:4849–4853
  6. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357:425–431
  7. Esteban NV, Yergey AL. Cortisol production rates measured by liquid chromatography/mass spectrometry. Steroids. 1990;55:152–158
  8. Kerrigan JR, Veldhuis JD, Leyo SA, et al. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. The Journal of Clinical Endocrinology and Metabolism. 1993;76:1505–1510
  9. Kraan GP, Dullaart RP, Pratt JJ, et al. The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. The Journal of Clinical Endocrinology and Metabolism. 1998;83:1247–1252
  10. Brandon DD, Isabelle LM, Samuels MH, et al. Cortisol production rate measurement by stable isotope dilution using gas chromatography-negative ion chemical ionization mass spectrometry. Steroids. 1999;64:372–378
  11. Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids. 2002;67:529–534
  12. Barbetta L, Dall'Asta C, Re T, et al. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism. Journal of Endocrinological Investigation. 2005;28:632–637
  13. Alonso N, Granada ML, Lucas A, et al. Evaluation of two replacement regimens in primary adrenal insufficiency patients. effect on clinical symptoms, health-related quality of life and biochemical parameters. Journal of Endocrinological Investigation. 2004;27:449–454
  14. Laureti S, Falorni A, Santeusanio F. Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. Journal of Endocrinological Investigation. 2003;26:1071–1075
  15. Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter?. Clinical Endocrinology. 1997;46:255–261
  16. Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clinical Endocrinology. 1997;46:263–268
  17. Mah PM, Jenkins RC, Rostami-Hodjegan A, et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clinical Endocrinology. 2004;61:367–375
  18. Arlt W, Rosenthal C, Hahner S, et al. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clinical Endocrinology. 2006;64:384–389
  19. Lovas K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease. European Journal of Endocrinology. 2007;157:109–112
  20. Newell-Price J, Whiteman M, Rostami-Hodjegan A, et al. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clinical Endocrinology. 2008;68:130–135
  21. Johannsson G, Filipsson H, Bergthorsdottir R, et al. Long-acting hydrocortisone for glucocorticoid replacement therapy. Hormone Research. 2007;68(Suppl. 5):182–188
  22. Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371:205–214
  23. Oelkers W, Diederich S, Bahr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. The Journal of Clinical Endocrinology and Metabolism. 1992;75:259–264
  24. Labrie F, Belanger A, Cusan L, et al. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. The Journal of Clinical Endocrinology and Metabolism. 1997;82:2403–2409
  25. Martel C, Melner MH, Gagne D, et al. Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. Molecular and Cellular Endocrinology. 1994;104:103–111
  26. Labrie F. Intracrinology. Molecular and Cellular Endocrinology. 1991;78:C113–C118
  27. Allolio B, Arlt W. DHEA treatment: myth or reality?. Trends in Endocrinology and Metabolism: TEM. 2002;13:288–294
  28. Hammer F, Drescher DG, Schneider SB, et al. Sex steroid metabolism in human peripheral blood mononuclear cells changes with aging. The Journal of Clinical Endocrinology and Metabolism. 2005;90:6283–6289
  29. Krazeisen A, Breitling R, Imai K, et al. Determination of cDNA, gene structure and chromosomal localization of the novel human 17beta-hydroxysteroid dehydrogenase type 7(1). FEBS Letters. 1999;460:373–379
  30. Hammer F, Subtil S, Lux P, et al. No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies. The Journal of Clinical Endocrinology and Metabolism. 2005;90:3600–3605
  31. Arlt W, Haas J, Callies F, et al. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. The Journal of Clinical Endocrinology and Metabolism. 1999;84:2170–2176
  32. Arlt W, Callies F, Koehler I, et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. The Journal of Clinical Endocrinology and Metabolism. 2001;86:4686–4692
  33. Callies F, Arlt W, Siekmann L, et al. Influence of oral dehydroepiandrosterone (DHEA) on urinary steroid metabolites in males and females. Steroids. 2000;65:98–102
  34. Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. The Journal of Neuroscience. 1996;16:1193–1202
  35. Majewska MD, Demirgoren S, Spivak CE, et al. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Research. 1990;526:143–146
  36. Petri MA, Mease PJ, Merrill JT, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis and Rheumatism. 2004;50:2858–2868
  37. Coles AJ, Thompson S, Cox AL, et al. Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+ CD25hi and CD4+ FoxP3+) T cells. European Journal of Immunology. 2005;35:3694–3703
  38. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). The Journal of Biological Chemistry. 2002;277:21379–21388
  39. Liu D, Iruthayanathan M, Homan LL, et al. Dehydroepiandrosterone stimulates endothelial proliferation and angiogenesis through extracellular signal-regulated kinase 1/2-mediated mechanisms. Endocrinology. 2008;149:889–898
  40. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. The New England Journal of Medicine. 1999;341:1013–1020
  41. Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. The Journal of Clinical Endocrinology and Metabolism. 2000;85:4650–4656
  42. Johannsson G, Burman P, Wiren L, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism. 2002;87:2046–2052
  43. Brooke AM, Kalingag LA, Miraki-Moud F, et al. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. The Journal of Clinical Endocrinology and Metabolism. 2006;91:3773–3779
  44. Gurnell EM, Hunt PJ, Curran SE, et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. The Journal of Clinical Endocrinology and Metabolism. 2008;93:400–409
  45. van Thiel SW, Romijn JA, Pereira AM, et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial. The Journal of Clinical Endocrinology and Metabolism. 2005;90:3295–3303
  46. Libe R, Barbetta L, Dall'Asta C, et al. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. Journal of Endocrinological Investigation. 2004;27:736–741
  47. Lovas K, Gebre-Medhin G, Trovik TS, et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. The Journal of Clinical Endocrinology and Metabolism. 2003;88:1112–1118
  48. Callies F, Fassnacht M, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. The Journal of Clinical Endocrinology and Metabolism. 2001;86:1968–1972
  49. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes. 2005;54:765–769
  50. Kim SS, Brody KH. Dehydroepiandrosterone replacement in addison's disease. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2001;97:96–97
  51. Allolio B, Hoffmann J, Linton EA, et al. Diurnal salivary cortisol patterns during pregnancy and after delivery: relationship to plasma corticotrophin-releasing-hormone. Clinical Endocrinology. 1990;33:279–289
  52. Suri D, Moran J, Hibbard JU, et al. Assessment of adrenal reserve in pregnancy: defining the normal response to the adrenocorticotropin stimulation test. The Journal of Clinical Endocrinology and Metabolism. 2006;91:3866–3872
  53. Lindsay JR, Nieman LK. The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocrine Reviews. 2005;26:775–799
  54. Diederich S, Bahr V, Oelkers W. Therapy of adrenal cortex insufficiency. Deutsche medizinische Wochenschrift. 1994;119:595–597
  55. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA : The Journal of the American Medical Association. 2002;288:862–871
  56. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Critical Care Medicine. 1999;27:723–732
  57. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. The New England Journal of Medicine. 2008;358:111–124
  58. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine. 2008;36:296–327
  59. Schlaghecke R, Kornely E, Santen RT, et al. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. The New England Journal of Medicine. 1992;326:226–230
  60. Nicholson G, Burrin JM, Hall GM. Peri-operative steroid supplementation. Anaesthesia. 1998;53:1091–1104
  61. Henzen C, Suter A, Lerch E, et al. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000;355:542–545
  62. Salem M, Tainsh RE, Bromberg J, et al. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Annals of Surgery. 1994;219:416–425
  63. Darzy KH, Shalet SM. Circadian and stimulated thyrotropin secretion in cranially irradiated adult cancer survivors. The Journal of Clinical Endocrinology and Metabolism. 2005;90:6490–6497
  64. Allolio B, Kaulen D, Deuss U, et al. Comparison between hydrocortisone and cortisone acetate as replacement therapyin adrenocortical insufficiency. Aktuelle Endokrinologie und Stoffwechsel. 1985;6:35–39

PII: S1521-690X(08)00107-3

doi: 10.1016/j.beem.2008.09.009

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 167-179 , April 2009

Article Tools

* Image Usage & Resolution